- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01277146
A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors
A Phase 1 Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors
This is an open-label Phase 1 dose escalation study of OMP-59R5 in subjects with previously treated solid tumors for which there is no remaining standard curative therapy and no therapy with a demonstrated survival benefit. Up to 44 subjects will be enrolled at up to 2 centers. Subjects will be assessed for safety, immunogenicity, pharmacokinetics, biomarkers, and efficacy. No formal interim analyses will be performed.
Prior to enrollment, subjects will undergo screening to determine study eligibility. Upon enrollment, subjects will receive intravenous (IV) infusions of OMP-59R5 at a assigned dosing schedule for 56 days. After 56 days, subjects will be assessed for disease status. If there is no evidence of disease progression or if the tumor is smaller, then subjects may continue to receive IV infusions of OMP-59R5 every week until disease progression.
Dose escalation will be conducted to determine the maximum tolerated dose (MTD). No dose escalation or reduction will be allowed within a dose cohort. The first 2 subjects enrolled in a cohort will not be treated on the same day. The dose may be administered at any time during the day. Three subjects will be treated at each dose level if no dose-limiting toxicities (DLTs) are observed. The first 2 subjects in each cohort will not be started on OMP-59R5 on the same day. If 1 of 3 subjects experiences a DLT, that dose level will be expanded to 6 subjects. If 2 or more subjects experience a DLT, no further subjects will be dosed at that level and 3 additional subjects will be added to the preceding dose cohort unless 6 subjects have already been treated at that dose level. Subjects will be assessed for DLTs from the time of the first dose through 28 days. Dose escalation for newly enrolled subjects, if appropriate, will occur after all subjects in a cohort have completed their Day 28 DLT assessment. Subjects with stable disease or a response at Day 56 will be allowed to continue to receive weekly doses of OMP-59R5 until disease progression. An additional 14 subjects will be enrolled at the highest dose level that result in <2 of the 6 subjects experiencing a DLT.
Aperçu de l'étude
Type d'étude
Inscription (Réel)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48109
- University of Michigan Comprehensive Cancer Center
-
-
Texas
-
San Antonio, Texas, États-Unis, 78229
- South Texas Accelerated Research Therapeutics
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Subjects must have a histologically confirmed malignancy that is metastatic or unresectable for which there is no remaining standard curative therapy and no therapy with a demonstrated survival benefit. In addition, subjects must have a tumor that is at least 1 cm in a single dimension and is radiographically apparent on CT or MRI.
- Subjects must have received their last chemotherapy, biologic, or investigational therapy at least 4 weeks prior to enrollment, 6 weeks if the last regimen included BCNU or mitomycin C.
- Age >18 years
- ECOG performance status <2 (see Appendix B)
- Life expectancy of more than 3 months
Subjects must have normal organ and marrow function as defined below:
- Absolute neutrophil count >1000/mL
- Hemoglobin >9.0 g/dL
- Platelets >100,000/mL
- Total bilirubin <1.5 X institutional upper limit of normal (ULN)
- AST (SGOT) and ALT (SGPT) < 3 X institutional ULN (for subjects with hepatic metastases < 5 X institutional ULN)
- PT and PTT within 1.5 X institutional ULN
- Creatinine <1.5 X institutional ULN OR
- Creatinine clearance >60 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal
- Women of childbearing potential must have had a prior hysterectomy or have a negative serum pregnancy test and be using adequate contraception prior to study entry and must agree to use adequate contraception from study entry through at least 6 months after discontinuation of study drug. Men must also agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and from study entry through at least 6 months after discontinuation of study drug. Should a woman enrolled in the study or a female partner of a man enrolled in the study become pregnant or suspect she is pregnant while participating in this study or within 6 months after discontinuation of study, she should inform the Investigator immediately.
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Subjects receiving any other investigational agents
- Subjects with brain metastases (subjects must have a CT scan or MRI of the head within 28 days prior to enrollment to rule out brain metastases), uncontrolled seizure disorder, or active neurologic disease
- History of a significant allergic reaction attributed to humanized or human monoclonal antibody therapy
- Significant intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant women or nursing women
- Subjects with known HIV infection
- Known bleeding disorder or coagulopathy
- Subjects receiving heparin, warfarin, or other similar anticoagulants, except for subjects on low molecular weight heparin for DVT/PE prophylaxis. Note: Subjects may be receiving low-dose aspirin and/or non-steroidal anti-inflammatory agents.
- New York Heart Association Classification II, III, or IV
- Subjects with a blood pressure of >140/90 mmHg. The blood pressure must be taken three times 10 minutes apart. Subjects taking antihypertensive medications must be taking ≤ 2 medications to obtain this level of blood pressure control.
- Subjects with EKG evidence of ischemia or ≥ Grade 2 ventricular arrhythmia, subjects who have a history of acute myocardial infarction within 6 months, or subjects with unstable angina.
- Subjects with known clinically significant gastrointestinal disease including, but not limited to, inflammatory bowel disease.
- Subjects with known clinically significant gastrointestinal disease including, but not limited to, inflammatory bowel disease.
- Subjects with >1 grade 1 diarrhea.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: OMP-59R5
|
IV infusion
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
To determine the safety of OMP-59R5 in subjects with previously treated solid tumors
Délai: continuous
|
The number of patients experiencing Adverse Events will be reported.
|
continuous
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
To determine the pharmacokinetics of OMP-59R5 in subjects with previously treated solid tumors
Délai: First 8 doses and following treatment termination
|
The half-life, volume of distribution, and clearance will be determined
|
First 8 doses and following treatment termination
|
To determine the immunogenicity of OMP-59R5 in subjects with previously treated solid tumors
Délai: continuous
|
The rate of neutralizing antibodies will be determined
|
continuous
|
To assess the preliminary efficacy of OMP-59R5 in subjects with previously treated solid tumors
Délai: continuous
|
The response outcome in patient will be determined
|
continuous
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: David C. Smith, MD, University of Michigan
- Chercheur principal: Anthony W. Tolcher, MD, South Texas Accelerated Research Therapeutics, LLC
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 59R5-001
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Tumeurs solides
-
AstraZenecaRecrutementAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian CancerEspagne, États-Unis, Belgique, Royaume-Uni, France, Hongrie, Canada, Corée, République de, Australie
-
Shattuck Labs, Inc.Actif, ne recrute pasMélanome | Carcinome à cellules rénales | Lymphome de Hodgkin | Adénocarcinome gastrique | Cancer du poumon non à petites cellules | Carcinome épidermoïde de la tête et du cou | Lymphome diffus à grandes cellules B | Carcinome urothélial | Adénocarcinome de la jonction gastro-oesophagienne | Carcinome... et d'autres conditionsÉtats-Unis, Canada, Belgique, Espagne
Essais cliniques sur OMP-59R5
-
OncoMed Pharmaceuticals, Inc.ComplétéTumeurs solides récidivantes ou réfractairesÉtats-Unis
-
OncoMed Pharmaceuticals, Inc.RésiliéCancer du poumon à petites cellules de stade IVÉtats-Unis
-
OncoMed Pharmaceuticals, Inc.ComplétéTumeurs solidesÉtats-Unis
-
OncoMed Pharmaceuticals, Inc.ComplétéMalignités lymphoïdes récidivantes ou réfractairesÉtats-Unis
-
OncoMed Pharmaceuticals, Inc.Novotech (Australia) Pty LimitedComplétéCancer colorectalAustralie, Nouvelle-Zélande
-
OncoMed Pharmaceuticals, Inc.BayerComplétéTumeurs solidesÉtats-Unis
-
OncoMed Pharmaceuticals, Inc.RésiliéCancer métastatique | Tumeur maligne localement avancéeÉtats-Unis
-
OncoMed Pharmaceuticals, Inc.ComplétéTumeurs solidesÉtats-Unis
-
M.D. Anderson Cancer CenterComplétéCarcinome adénoïde kystiqueÉtats-Unis
-
OncoMed Pharmaceuticals, Inc.ComplétéTumeurs solides réfractaires | Tumeurs récidivantes avancéesÉtats-Unis